Compare Torrent Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA STRIDES PHARMA SCIENCE TORRENT PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 55.1 8.1 675.9% View Chart
P/BV x 6.6 1.0 676.3% View Chart
Dividend Yield % 0.8 0.5 156.0%  

Financials

 TORRENT PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
TORRENT PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,5501,147 135.1%   
Low Rs1,144642 178.1%   
Sales per share (Unadj.) Rs354.7317.2 111.8%  
Earnings per share (Unadj.) Rs40.17.8 510.8%  
Cash flow per share (Unadj.) Rs64.225.1 256.3%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %1.00.2 464.9%  
Book value per share (Unadj.) Rs273.1274.3 99.6%  
Shares outstanding (eoy) m169.2289.50 189.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.82.8 134.7%   
Avg P/E ratio x33.6114.0 29.5%  
P/CF ratio (eoy) x21.035.7 58.7%  
Price / Book Value ratio x4.93.3 151.2%  
Dividend payout %34.925.5 137.0%   
Avg Mkt Cap Rs m227,89780,058 284.7%   
No. of employees `00014.72.5 586.4%   
Total wages/salary Rs m11,3534,341 261.5%   
Avg. sales/employee Rs Th4,083.011,325.8 36.1%   
Avg. wages/employee Rs Th772.31,731.4 44.6%   
Avg. net profit/employee Rs Th461.3280.1 164.7%   
INCOME DATA
Net Sales Rs m60,02128,394 211.4%  
Other income Rs m2,988941 317.7%   
Total revenues Rs m63,00929,334 214.8%   
Gross profit Rs m13,4933,965 340.3%  
Depreciation Rs m4,0861,540 265.3%   
Interest Rs m3,0851,962 157.2%   
Profit before tax Rs m9,3101,403 663.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m2,52997 2,598.9%   
Profit after tax Rs m6,781702 965.9%  
Gross profit margin %22.514.0 161.0%  
Effective tax rate %27.26.9 391.7%   
Net profit margin %11.32.5 456.9%  
BALANCE SHEET DATA
Current assets Rs m52,62324,836 211.9%   
Current liabilities Rs m52,02218,993 273.9%   
Net working cap to sales %1.020.6 4.9%  
Current ratio x1.01.3 77.4%  
Inventory Days Days12071 168.5%  
Debtors Days Days76113 67.2%  
Net fixed assets Rs m85,01634,289 247.9%   
Share capital Rs m846895 94.5%   
"Free" reserves Rs m45,37623,651 191.9%   
Net worth Rs m46,22224,546 188.3%   
Long term debt Rs m41,11515,513 265.0%   
Total assets Rs m142,43265,437 217.7%  
Interest coverage x4.01.7 234.3%   
Debt to equity ratio x0.90.6 140.7%  
Sales to assets ratio x0.40.4 97.1%   
Return on assets %6.94.1 170.1%  
Return on equity %14.72.9 512.9%  
Return on capital %14.26.9 205.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58015,697 92.9%   
Fx outflow Rs m3,600735 489.5%   
Net fx Rs m10,98014,962 73.4%   
CASH FLOW
From Operations Rs m8,9421,871 478.0%  
From Investments Rs m-47,0705,826 -807.9%  
From Financial Activity Rs m34,174-10,157 -336.5%  
Net Cashflow Rs m-3,655-2,615 139.8%  

Share Holding

Indian Promoters % 71.5 27.7 258.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 37.8 18.6%  
FIIs % 12.6 8.6 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 25.9 34.0%  
Shareholders   26,511 56,241 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  PLETHICO PHARMA  FDC LTD.  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Generate Alpha over the Next Decade(Profit Hunter)

Oct 29, 2019

Here's your chance benefit from a safe approach to making money in stock markets .

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Nov 11, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS